Indomethacin - CAS 53-86-1
Category:
APIs
Product Name:
Indomethacin
Catalog Number:
53-86-1
Synonyms:
Indomethacin; Indometacin; Indocin.
CAS Number:
53-86-1
Description:
Indomethacin is a synthetic nonsteroidal indole derivative with anti-inflammatory activity and chemopreventive properties. As a nonsteroidal anti-inflammatory drug (NSAID), indomethacin inhibits the enzyme cyclooxygenase, thereby preventing cyclooxygenase-mediated DNA adduct formation by heterocyclic aromatic amines. This agent also may inhibit the expression of multidrug-resistant protein type 1, resulting in increased efficacies of some antineoplastic agents in treating multi-drug resistant tumors. In addition, indomethacin activates phosphatases that inhibit the migration and proliferation of cancer cells and downregulates survivin, which may result in tumor cell apoptosis.
Molecular Weight:
357.79
Molecular Formula:
C19H16ClNO4
Quantity:
Grams-Kilos
Quality Standard:
BP
COA:
Specification Sheet-Indomethacin 53-86-1  
MSDS:
Inquire
GMP:
GMP
Targets:
Cyclooxygenase
Chemical Structure
CAS 53-86-1 Indomethacin

Related Products


CAS 104-88-1 4-Chlorobenzaldehyde

4-Chlorobenzaldehyde
(CAS: 104-88-1)

CAS 14985-18-3 ZIRCONYL NITRATE HYDRATE

ZIRCONYL NITRATE HYDRATE
(CAS: 14985-18-3)

CAS 1601-18-9 Indomethacin

Indomethacin
(CAS: 1601-18-9)

CAS 16401-99-3 Indomethacin Ethyl Ester

Indomethacin Ethyl Ester
(CAS: 16401-99-3)

an impurity of Indomethacin

CAS 2504-32-7 O-Desmethyl Indomethacin

O-Desmethyl Indomethacin
(CAS: 2504-32-7)

The major metabolite of Indomethacin

CAS 261766-32-9 N-(2-phenylethyl)-Indomethacin amide

N-(2-phenylethyl)-Indomethacin amide
(CAS: 261766-32-9)

A potent elective reversible inhibitors of COX-2

CAS 27035-30-9 Oxametacin

Oxametacin
(CAS: 27035-30-9)

CAS 2854-32-2 BML-190

BML-190
(CAS: 2854-32-2)

BML-190 is a selective cannabinoid CB2 receptor inverse agonist with Ki of 435 nM, with 50-fold selectivity over CB1 receptor.

CAS 2854-32-2 Indomethacin morpholinylamide

Indomethacin morpholinylamide
(CAS: 2854-32-2)

An aminoalkylindole ligand; highly selective for cannabinoid CB2 receptor

CAS 53164-05-9 Acemetacin

Acemetacin
(CAS: 53164-05-9)

COX inhibitor; A non-steroidal anti-inflammatory drug

CAS 53164-05-9 Acemetacin

Acemetacin
(CAS: 53164-05-9)

Acemetacin is a non-steroidal anti-inflammatory drug, used for the treatment of osteoarthritis, rheumatoid arthritis, lower back pain, and relieving post-operat...

CAS 74-11-3 4-Chlorobenzoic acid

4-Chlorobenzoic acid
(CAS: 74-11-3)

CAS 75302-98-6 ACEMETACINTERT-BUTYLESTER

ACEMETACINTERT-BUTYLESTER
(CAS: 75302-98-6)

CAS 75523-11-4 Indomethacin acyl glucuronide

Indomethacin acyl glucuronide
(CAS: 75523-11-4)

a metabolite of Indomethacin

Reference Reading


1. Microfluidic approach to polymorph screening through antisolvent crystallization
Michael R. Thorson, Sachit Goyal, Yuchuan Gong,* Geoff G. Z. Zhangb and Paul J. A. Kenis*. CrystEngComm, 2012, 14, 2404–2412
To calculate supersaturation profiles for indomethacin (see below), we estimated the solubility of indomethacin experimentally as the solubility data of indomethacin in a binary solution of methanol and water was not available in the literature. Indomethacin was added to five, 20-mL glass vials (Kimmble/Chase). Mixtures of methanol and water (methanol to water volumetric ratios of 10 : 1, 8 : 2, 7 : 3, 6 : 4, and 5 : 5) were pipetted into glass vials with an incremental volume of 0.5 ml, 2 ml, or 5 ml depending on the total volume of the added solvent.
2. Gastroprotective potential against indomethacin and safety assessment of the homology of medicine and food formula cuttlebone complex
Mei-Yin Chien, Yi-Ting Lin, Chih-Min Yang* and Chao-Hsiang Chen*. Food Funct.,2015, 6,2803–2812
The rats were orally pre-treated once with indomethacin for 1 h, and then orally received CBC once for 4 h to determine the therapeutic effects of CBC against gastric ulceration induced by indomethacin. All of the 8 mice in the indomethacin-treated group developed gastric ulcers, whereas 6 and 3 of the 8 mice in the medium- and high-CBC group developed gastric ulcers, respectively. Indomethacin treatment significantly increased the ulcer index, ulcerous lesions, and erosion and blood congestion, but decreased the PGE2 content.
3. Characterisation of organic solid forms and real-time in situ monitoring of their transformations using solid-state fluorescence
Mathieu Frenette, Gonzalo Cosa* and Tomislav Friscic*. CrystEngComm, 2013, 15, 5100–5106
To obtain indomethacin methanol solvate, a saturated solution of indomethacin in boiling methanol was further diluted with methanol and cooled to yield pale yellow needles. The needles were recovered by filtration, washed with cold methanol, dried under vacuum and kept in a sealed vial at room temperature. The PXRD and DSC data matched those reported for the crystalline methanol solvate (CSD code BANMUZ). For the synthesis of a-indomethacin, water was added to the recrystallisation supernatant, immediately yielding a white precipitate. Filtration and thorough drying under vacuum yielded a-indomethacin as previously described.